1 - 25 of 32 results for author:"Basolo F." in Literature citations
Results Customize
› Repeat search in UniProtKB (1)
| The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. Elisei R., Viola D., Torregrossa L., Giannini R., Romei C., Ugolini C., Molinaro E., Agate L., Biagini A., Lupi C. et al. J. Clin. Endocrinol. Metab. 97:4390-4398(2012) · Mapped (3) |
| FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. Bellelli R., Castellone M.D., Garcia-Rostan G., Ugolini C., Nucera C., Sadow P.M., Nappi T.C., Salerno P., Cantisani M.C., Basolo F. et al. Endocr. Relat. Cancer 19:695-710(2012) · Mapped (3) |
| Higher intratumoral expression of CD1a, tryptase, and CD68 in a follicular variant of papillary thyroid carcinoma compared to adenomas: correlation with clinical and pathological parameters. Proietti A., Ugolini C., Melillo R.M., Crisman G., Elisei R., Santoro M., Minuto M., Vitti P., Miccoli P., Basolo F. Thyroid 21:1209-1215(2011) · Mapped (5) |
| CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas. Torregrossa L., Giannini R., Borrelli N., Sensi E., Melillo R.M., Leocata P., Materazzi G., Miccoli P., Santoro M., Basolo F. Mod. Pathol. 25:46-55(2012) · Mapped (5) |
| TWIST1 plays a pleiotropic role in determining the anaplastic thyroid cancer phenotype. Salerno P., Garcia-Rostan G., Piccinin S., Bencivenga T.C., Di Maro G., Doglioni C., Basolo F., Maestro R., Fusco A., Santoro M. et al. J. Clin. Endocrinol. Metab. 96:E772-81(2011) · Mapped (1) |
| BRAF status of follicular variant of papillary thyroid carcinoma and its relationship to its clinical and cytological features. Proietti A., Giannini R., Ugolini C., Miccoli M., Fontanini G., Di Coscio G., Romani R., Berti P., Miccoli P., Basolo F. Thyroid 20:1263-1270(2010) · Mapped (3) |
| Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. Basolo F., Torregrossa L., Giannini R., Miccoli M., Lupi C., Sensi E., Berti P., Elisei R., Vitti P., Baggiani A. et al. J. Clin. Endocrinol. Metab. 95:4197-4205(2010) · Mapped (3) |
| Extracellular superoxide dismutase is a thyroid differentiation marker down-regulated in cancer. Laatikainen L.E., Castellone M.D., Hebrant A., Hoste C., Cantisani M.C., Laurila J.P., Salvatore G., Salerno P., Basolo F., Nasman J. et al. Endocr. Relat. Cancer 17:785-796(2010) · Mapped (3) |
| CXC chemokine receptor 4 immunodetection in the follicular variant of papillary thyroid carcinoma: comparison to galectin-3 and hector battifora mesothelial cell-1. Torregrossa L., Faviana P., Filice M.E., Materazzi G., Miccoli P., Vitti P., Fontanini G., Melillo R.M., Santoro M., Basolo F. Thyroid 20:495-504(2010) · Mapped (11) |
| KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Loupakis F., Ruzzo A., Cremolini C., Vincenzi B., Salvatore L., Santini D., Masi G., Stasi I., Canestrari E., Rulli E. et al. Br. J. Cancer 101:715-721(2009) · Mapped (11) |
| Functional characterization of the novel T599I-VKSRdel BRAF mutation in a follicular variant papillary thyroid carcinoma. De Falco V., Giannini R., Tamburrino A., Ugolini C., Lupi C., Puxeddu E., Santoro M., Basolo F. J. Clin. Endocrinol. Metab. 93:4398-4402(2008) · Mapped (3) |
| BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. Elisei R., Ugolini C., Viola D., Lupi C., Biagini A., Giannini R., Romei C., Miccoli P., Pinchera A., Basolo F. J. Clin. Endocrinol. Metab. 93:3943-3949(2008) · Mapped (3) |
| BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Romei C., Ciampi R., Faviana P., Agate L., Molinaro E., Bottici V., Basolo F., Miccoli P., Pacini F., Pinchera A. et al. Endocr. Relat. Cancer 15:511-520(2008) · Mapped (5) |
| Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Bartolazzi A., Orlandi F., Saggiorato E., Volante M., Arecco F., Rossetto R., Palestini N., Ghigo E., Papotti M., Bussolati G. et al. Lancet Oncol. 9:543-549(2008) · Mapped (9) |
| Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. De Falco V., Guarino V., Avilla E., Castellone M.D., Salerno P., Salvatore G., Faviana P., Basolo F., Santoro M., Melillo R.M. Cancer Res. 67:11821-11829(2007) · Mapped (2) |
| A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Salvatore G., Nappi T.C., Salerno P., Jiang Y., Garbi C., Ugolini C., Miccoli P., Basolo F., Castellone M.D., Cirafici A.M. et al. Cancer Res. 67:10148-10158(2007) · UniProtKB (1) |
| Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. Lupi C., Giannini R., Ugolini C., Proietti A., Berti P., Minuto M., Materazzi G., Elisei R., Santoro M., Miccoli P. et al. J. Clin. Endocrinol. Metab. 92:4085-4090(2007) · Mapped (3) |
| Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity. Torregrossa L., Faviana P., Camacci T., Materazzi G., Berti P., Minuto M., Elisei R., Vitti P., Miccoli P., Basolo F. Hum. Pathol. 38:1482-1488(2007) · Mapped (9) |
| Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Ugolini C., Giannini R., Lupi C., Salvatore G., Miccoli P., Proietti A., Elisei R., Santoro M., Basolo F. Thyroid 17:381-388(2007) · Mapped (3) |
| The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. Giannini R., Ugolini C., Lupi C., Proietti A., Elisei R., Salvatore G., Berti P., Materazzi G., Miccoli P., Santoro M. et al. J. Clin. Endocrinol. Metab. 92:3511-3516(2007) · Mapped (3) |
| Tumour necrosis factor-alpha: prognostic role and relationship with interleukin-8 and endothelin-1 in non-small cell lung cancer. Boldrini L., Gisfredi S., Ursino S., Lucchi M., Melfi F., Mussi A., Basolo F., Fontanini G. Int. J. Mol. Med. 17:887-892(2006) · Mapped (6) |
| Osteopontin expression and prognostic significance in non-small cell lung cancer. Donati V., Boldrini L., Dell'Omodarme M., Prati M.C., Faviana P., Camacci T., Lucchi M., Mussi A., Santoro M., Basolo F. et al. Clin. Cancer Res. 11:6459-6465(2005) · Mapped (8) |
| Interleukin-8 in non-small cell lung carcinoma: relation with angiogenic pattern and p53 alterations. Boldrini L., Gisfredi S., Ursino S., Lucchi M., Mussi A., Basolo F., Pingitore R., Fontanini G. Lung Cancer 50:309-317(2005) · Mapped (34) |
| Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. Guarino V., Faviana P., Salvatore G., Castellone M.D., Cirafici A.M., De Falco V., Celetti A., Giannini R., Basolo F., Melillo R.M. et al. J. Clin. Endocrinol. Metab. 90:5270-5278(2005) · Mapped (10) |
| Proliferative activity of extracellular HIV-1 Tat protein in human epithelial cells: expression profile of pathogenetically relevant genes. Bettaccini A.A., Baj A., Accolla R.S., Basolo F., Toniolo A.Q. BMC Microbiol. 5:20-20(2005) · Mapped (1) |